Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (6846)	2/23/2000 12:33:00 PM
From: RockyBalboa	Read Replies (1) \| Respond to of 10293

The bickering will presumably go on until Gum is either acquired or bakrupt, whichever comes earlier. I'm not surprised that it does not run while (almost) everything is moving with a "bio" tag on it. At the same time, I'm impressed that BW has himself converted from a value investor into a momentum investor (or "new" value investor). As a sort of irony, the incarnation of "value" stock, MO does a weird sort of deadcad bounce these days.

To: Hank who wrote (6846)	2/23/2000 10:55:00 PM
From: DanZ	Read Replies (2) \| Respond to of 10293

Citadel sold some GUMM during the rally to 35 and this could have accounted for some of the supply on the market. They are now paid completely off with very little dilution and their shares have all been sold. The market absorbed their supply with a minor correction and the stock has now based and is ready to resume the rally (IMO). Any pressure that Citadel put on the stock had nothing to do with the future fundamentals of the company, which is why I think that the stock is a good buy into the weakness that they might have caused. In general, I don't think that institutions buy stocks for a quick trade. Most of them buy based on fundamental analysis and only sell when the fundamentals change or when they think that the valuation is too far ahead of the future fundamentals. There's a reason why the institutional sponsorship has increased five straight quarters. They are obviously impressed with ten consecutive quarterly increases in revenue comparisons, a stronger balance sheet with a nice wad of cash and no debt, the company's first profitable quarter in several years, nicotine gum production in Q3 or Q4, other new products under development, patent protection for Zicam, a wide open world-wide market for Zicam, and a marginal profit that will make today's stock price look cheap in the not too distant future. Of course the institutional holdings are still relatively small, but the trend is what is important. Do you expect the institutional holdings to go from 0% to 50% in one quarter? If I was short, I'd be concerned about the trend in institutional buying. The institutions sold a measly 500 shares last quarter and that was probably an individual that owned stock through a bank (not really an institution holding). They are quickly buying up more of the already small float and you might be on the wrong side of a massive short squeeze in the not too distant future.